Where Avidity Biosciences Stands With Analysts
Portfolio Pulse from Benzinga Insights
Avidity Biosciences (NASDAQ:RNA) has received positive analyst ratings in the last quarter, with 3 bullish and 1 somewhat bullish ratings. The company's average price target has increased by 4.63% from the previous average of $27.00 to $28.25.
August 09, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avidity Biosciences has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up.
Analyst ratings often influence investor sentiment. The positive ratings for Avidity Biosciences indicate a favorable outlook for the company, which could lead to increased demand for the stock and a potential increase in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100